Bioequivalence trials of rifampicin containing formulations: Extrinsic and intrinsic factors in the absorption of rifampicin

Pharmacological Research

Volumn 50, Issue 3, 2004, Pages 317-327

  Agrawal, Shrutidevi ^a   Singh, Inderjit ^a   Kaur, Kanwal Jit ^a   Bhade, Shantaram ^a   Kaul, Chaman Lal ^a   Panchagnula, Ramesh ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Bioavailability; Bioequivalence; Fixed dose combination; Isoniazid; Pyrazinamide; Rifampicin; Tuberculosis

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ARTICLE; BIOEQUIVALENCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG MANUFACTURE; DRUG PENETRATION; DRUG SOLUBILITY; EVALUATION; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS; CONFIDENCE INTERVALS; HUMANS; INTESTINAL ABSORPTION; MIDDLE AGED; RIFAMPIN; THERAPEUTIC EQUIVALENCY;

EID: 3042640317     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2004.01.009     Document Type: Article

References (40)

1. Binda G., Domenichini E., Gottardi A. Rifampicin a general review. Arzneinmittelforschung. 21:1971;1908-1977
2. Kenny M.T., Strates B. Metabolism and pharmacokinetics of the antibiotic rifampicin. Drug Metab. Rev. 12:1981;159-218
3. Acocella G., Conti R., Luisetti M., Pozzi E., Grassi C. Pharmacokinetic studies on antituberculosis regimens in humans. I. Absorption and metabolism of the compounds used in the initial intensive phase of the short course regimens: single administration study. Am. Rev. Respir. Dis. 132:1985;510-515
4. Acocella G. Human bioavailability studies. IUATLD Symposium "Quality control of anti-tuberculosis drugs", Dubrovnik, 6 October 1988. Bull. Int. Union Tuberc. Lung Dis. 64:1989;38-40
5. Cavenaghi R. Rifampicin raw material characteristics and their effect on bioavailability. Bull. Int. Union Tuberc. Lung Dis. 64:1989;36-37
6. Pillai G., Fourie P., Padayatchi N., Onyebujoh P., McIlleron H., Smith P., et al. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market. Int. J. Tuberc. Lung Dis. 3:1999;S309-S316
7. Agrawal S., Kaur K.J., Singh I., Bhade S.R., Kaul C.L., Panchagnula R. Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels. Int. J Pharm. 233:2002;169-177
8. Ellard G.A., Fourie P.B. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption. Int. J Tuberc. Lung Dis. 3:1999;S301-S308
9. Gallo CG, Radaelli P. Rifampicin. In: Florey K, editor. Analytical profiles of drug substances. London: Academic Press; 1976. p. 467-513.
10. Zwolska Z., Niemirowska-Mikulska H., Augustynowicz-Kopec E., Walkiewicz R., Stambrowska H., Safinowska A., et al. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsule. Int. J Tuberc. Lung Dis. 2:1998;824-830
11. Panchagnula R., Sood A., Sharda N., Kaur K.J., Kaul C.L. Analysis of rifampicin and its main metabolite in presence of pyrazinamide and isoniazid in plasma and urine samples by HPLC method. J Pharm. Biomed. Anal. 18:1999;1505-1522
12. Panchagnula R., Kaur K.J., Singh I., Kaul C.L. The WHO simplified study protocol in practice investigation of combined formulations supplied by the WHO. Int. J Tuberc. Lung Dis. 3:1999;S336-S342
13. Panchagnula R., Singh I., Kaur K.J., Kaul C.L. Bioequivalence of rifampicin from two drugs fixed-dose combined formulation compared to separate formulations. Methods Find Exp. Clin. Pharmacol. 21:1999;625-628
14. Panchagnula R., Kaur K.J., Singh I., Kaul C.L. Bioequivalence of rifampicin when administered as a fixed-dose combined formulation of four drugs versus separate formulations. Methods Find Exp. Clin. Pharmacol. 22:2000;689-694
15. Agrawal S., Singh I., Kaur K.J., Bhade S.R., Kaul C.L., Panchagnula R. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid pyrazinamide and ethambutol vs. separate formulations at the same dose levels. Int. J Clin. Pharmacol. Ther. 40:2002;474-481
16. Agrawal S, Kaur KJ, Singh I, Bhade SR, Kaul CL, Panchagnula R. Bioequivalence determination of rifampicin, isoniazid and pyrazinamide from three drug fixed dose combination tablet of anti-tuberculosis drugs by both WHO and Indian DCGI protocols: influence of sampling schedule and size; 2004 (communicated).
17. Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels; 2004 (communicated).
18. Agrawal S, Kaur KJ, Singh I, Bhade SR, Kaul CL, Panchagnula R. Minimum sample size and sampling time requirements for assessment of rifampicin bioequivalence from fixed dose combination formulations. Int J Pharm 2004; in press.
19. Fourie B, Pillai G, Mclleron H, Smith P, Panchagnula R, Ellard G. Establishing the bioequivalence of rifampicin in fixed dose formulations containing isoniazid with or without pyrazinamide and/or ethambutol compared to single drug reference preparations administered in loose combination (Model Protocol), World Health Organization, WHO/CDS/TB/99.274, 1999; 1999.
20. Government of India. Schedule Y: requirements and guidelines on clinical trials for import and manufacture of new drugs. In: Malik V, editor. The drugs and cosmetics rules, 1945, drugs (price control) order, 1995 (as amended upto First Amendment of 1999), 12th ed. Lucknow, India: Eastern Book Company; 1999. p. 394-404.
21. Agrawal S., Kaul C.L., Panchagnula R. Bioequivalence of isoniazid in two drug fixed dose combination and in a single drug dosage form. Pharmazie. 56:2001;636-639
22. Ritschel WA, Kearns GL. Handbook of basic pharmacokinetics including clinical applications. 5th ed. Washington: American Pharmaceutical Association; 1999. p. 242-69, 296-303.
23. Hauschke D., Steinijans V.W., Diletti E.A. Distribution free procedure for the statistical analysis of bioequivalence studies. Int. J Clin. Pharmacol. Ther. Toxicol. 28:1990;72-78
24. Laing R, Fourie B, Ellard G, Sesay M, Spinaci S, Blomberg B, et al. Fixed-dose combination tablets for the treatment of tuberculosis. Report of an informal meeting held in Geneva Tuesday, 27 April 1999, World Health Organization, Geneva, WHO/CDS/CPC/TB/99.267; 1999.
25. Buniva G., Pagani V., Carozzi A. Bioavailability of rifampicin capsules. Int. J. Clin. Pharmacol. 21:1983;404-409
26. Sen H, Jindal KC, Deo KD, Gandhi KT. An improved process for preparation of four-drug anti-tubercular fixed dose combination. International Patent WO 02/087547 A1; 2002.
27. Boman G., Lundgren P., Stjernstrom G. Mechanism of the inhibitory effect of PAS granules on the absorption of rifampicin: adsorption of rifampicin by an excipients bentonite. Eur. J. Clin. Pharmacol. 8:1975;293-299
28. McIlleron H., Wash P., Burger A., Folb P., Smith P. Widespread distribution of a single drug rifampicin formulation of inferior bioavailability in South Africa. Int. J. Tuberc. Lung Dis. 6:2002;356-361
29. Pelizza G., Nebuloni M., Ferrari P., Gallo G.G. Polymorphism of rifampicin. II. Farmaco. 32:1977;471-481
30. Furesz S. Rifampicin: chemical and biological properties of rifampicin. Antibiot. Chemother. 16:1970;316-351
31. Loos U., Musch E., Jensen J.C., Mikus G., Schwabe H.K., Eichelbaum M. Influence of enzyme induction by rifampicin on its presystemic metabolism. Pharmacol. Ther. 33:1987;201-224
32. Curci G., Bergamini N., Delli V.F., Ninni A., Nitti V. Half-life of rifampicin after repeated administration of different doses in humans. Chemotherapy. 17:1972;373-381
33. Dickinson J.M., Mitchison D.A., Lee S.K. Serum rifampicin concentration related to dose size and to the incidence of the 'flu' syndrome during intermittent rifampicin administration. J. Antimicrob. Chemother. 3:1977;445-452
34. Acocella G., Pagani V., Marchetti M., Baroni G.C., Nicolis F.B. Kinetic studies on rifampicin: 1. Serum concentration analysis in subjects treated with different oral doses over a period of two weeks. Chemotherapy. 16:1971;356-370
35. Brechbuhler S., Flueher H., Riess W., Theobald W. The renal elimination of rifampicin as a function of oral dose. A convenient way to assess relative bioavailability. Arzneimittelforschung. 28:1978;480-483
36. Agrawal S, Panchagnula R. Implication of biopharmaceutic and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms; 2004 (communicated).
37. Anonymous. In: Colin D, editor. Ethambutol, isoniazid, pyrazinamide and rifampicin in therapeutic drugs. 2nd ed. Edinburgh: Churchill Livingstone; 1999. p. E68-72, I92-9, P287-9, R32-6.
38. Peloquin C.A., Bulpitt A.E., Jaresko G.S., Jelliffe R.W., Childs J.M., Nix D.E. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob. Agents Chemother. 43:1999;568-572
39. Weber W.W., Hein D.W. Clinical pharmacokinetics of isoniazid. Clin. Pharmacokinet. 4:1979;401-422
40. Panchagnula R., Sancheti P., Rungta S., Agrawal S., Kaul C.L. Evaluation of bioequivalence of isoniazid and pyrazinamide in three and four drugs fixed dose combinations using WHO simplified protocol. Pharmacol. Res. 48:2003;383-387